Eluxadoline Synthesis: High Yield and Purity via Controlled Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing processes for preparing Eluxadoline, a treatment for irritable bowel syndrome, suffer from low yield, purity issues, and environmental concerns due to cumbersome workups and the generation of significant waste, making them unsuitable for commercial scale-up.
Innovation Solution
An improved process involving the reaction of acid addition salts with suitable coupling agents and bases in specific solvents to produce the amorphous form of Eluxadoline, which includes crystalline forms and solvates, with a focus on high yield, purity, and reduced environmental impact.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional processes are used to prepare Eluxadoline, then the compound can be obtained, but the yield is low and purity is poor
Solution Approach 1:
The patent employs parameter changes by optimizing reaction conditions including solvent selection (dichloromethane, ethyl acetate, or their mixtures), temperature control (0-25°C), and stoichiometric ratios of reagents. These parameter optimizations enable simultaneous achievement of high yield (85-95%) and high purity (>98%) by controlling the crystallization process and minimizing side reactions
2Ease of manufacture
If conventional workup procedures are used, then the compound can be isolated, but the process is cumbersome and generates significant waste
Solution Approach 1:
The patent applies extraction principles by utilizing the solubility differences of Eluxadoline in various solvents. The compound is selectively extracted and crystallized from reaction mixtures using dichloromethane or ethyl acetate, allowing direct isolation of pure product without cumbersome filtration and purification steps. This approach eliminates the need for multiple washing and purification operations that generate waste
Solution Approach 2:
The patent implements self-service through self-assembly crystallization where Eluxadoline automatically crystallizes in high purity form from the reaction medium upon controlled evaporation or cooling. The compound's inherent solubility characteristics enable it to self-purify during the crystallization process, eliminating the need for additional purification steps and reducing waste generation
3Ease of operation
If conventional isolation methods are used, then the compound can be obtained, but it forms a gummy semi-solid that is difficult to isolate
Solution Approach 1:
The patent applies phase transition principles by controlling the crystallization of Eluxadoline from liquid reaction mixtures to solid crystalline form. By adjusting temperature, solvent composition, and evaporation rate, the compound transitions directly from dissolved state to well-formed crystals rather than forming gummy semi-solids. This phase control enables easy filtration and isolation of pure crystalline product
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high yield and purity of Eluxadoline with reduced environmental footprint, overcoming the limitations of previous methods by simplifying the process and minimizing waste generation.
Implementation Method 1
Reacting acid addition salts of (S)-methyl-2-methoxy-5-(((1-(4-phenyl-1H-imidazol-2-yl)ethyl)amino)methyl)benzoate compound of formula-2 with (S)-2-((tert-butoxycarbonyl)amino)-3-(4-carbamoyl-2,6-dimethylphenyl)propanoic acid compound of formula-3 in presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl, 1-hydroxybenzotriazole and diisopropylethylamine in acetonitrile
Implementation Method 2
treating the compound of formula-4 with aqueous lithium hydroxide in the presence of tetrahydrofuran and methanol for 2-5 hours at 25-40°C
Implementation Method 3
The said process suffers from several drawbacks such as cumbersome workup, compound of formula-1 is obtained as gummy semi-solid which is difficult to isolate and requires tedious purifications
Data Source
AI summary
The present invention relates to an improved process for the preparation of 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid compound of formula-1, and polymorphs thereof, the compound of formula-1 is further represented by the following structural formula: